EIPR stresses the importance of issuing this law in a timely manner. The presidency’s objections should not be used to justify a delay given the importance of this legislation and its direct impact on the health and rights of Egyptians as well as scientific research. We also stress on the importance of releasing drafts to the media and civil society, to enable the assembly to pass a law that receives the support of stakeholders and makes them partners in its implementation.
Tags: Clinical Trials
EIPR believes that the Egyptian government should negotiate with the new drug manufacturer from a position of strength as this drug cannot be imported without receiving an Egyptian license and conducting the needed clinical trials.